Blood Science Update | A Promising Leap in Treating Large Granular Lymphocytic Leukemia with Thalidomide-Based Therapy
The commentary “A Promising Leap in Treating Large Granular Lymphocytic Leukemia: Reflections on a Multicenter Phase II Study of Thalidomide-Based Therapy” by Xue Kong and Ken H. Young from Duke…
Microbiota Modulation: A New Pillar in aGVHD Treatment
Professor Mohamad Mohty, Head of the Hematology and Cellular Therapy Department at Saint-Antoine Hospital and Sorbonne University, Paris, discusses a paradigm shift in managing acute graft-versus-host disease (aGVHD).He highlights the critical role of gut microbiota dysbiosis in the pathogenesis of aGVHD following allogeneic hematopoietic stem cell transplantation and elaborates on the therapeutic potential of microbiota modulation.
CCHIO 2025 | Professor Zhu Jun: Breaking Barriers and Shaping Momentum — A New Blueprint for CAR-T in China Driven by Policy, Payment, and Innovation
From November 6 to 9, 2025, the China Conference on Holistic and Integrative Oncology (CCHIO 2025) was successfully held in Kunming. As one of the largest and most influential oncology…
ASH China Voice丨Zunmin Zhu / Mingfeng Zhao / Wenyi Lu: IL-18 and RQR8 Suicide-Switch Dual-Armored CLL-1 CAR-T Cells Enhance the Efficacy and Safety of AML Therapy
The 67th American Society of Hematology (ASH) Annual Meeting will be held from December 6 to 9, 2025, in Orlando, USA. As one of the largest, most influential, and most comprehensive international congresses in hematology, ASH attracts tens of thousands of experts and scholars from around the world each year to share the latest advances and breakthrough research in the field.
Adv Sci | MARCO⁺ Tumor-Associated Macrophages Drive Immunotherapy Resistance in Renal Cell Carcinoma
Renal cell carcinoma (RCC) is the most common subtype of kidney cancer and continues to rise in incidence worldwide. RCC is also regarded as one of the most immune- and…